Prosecution Insights
Last updated: November 12, 2026
Application No. 18/896,681

AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED

Non-Final OA §102§103
Filed
Sep 25, 2024
Priority
Sep 20, 2018 — JP 2018-176473 +2 more
Examiner
HA, JULIE
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nrl Pharma Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
854 granted / 1127 resolved
+15.8% vs TC avg
Strong +44% interview lift
Without
With
+44.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
44 currently pending
Career history
1175
Total Applications
across all art units

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Response to Election/Restriction filed on September 14, 2026, is acknowledged. 3. Claims 1-10 are pending in this application. Information Disclosure Statement 4. It is noted that Applicants have not filed an information disclosure statementunder § 1.97(c). Applicant is reminded of 37 CFR § 1.56, which details Applicants dutyto disclose all information known to be material to patentability. Please note: the specification refers to Non-patent literature (see paragraphs [0012]-[0022] of instant specification US 2025/0009848). This is not a proper way to disclose IDS. Applicant is required to properly disclose all information known to be material to patentability by filing an Information Disclosure Statement. Priority 5. Applicant claims foreign priority to JAPAN 2018-176473 (9/20/2018). The certified copy has been received by the Office. However, a certified English translation has not been provided. Therefore, the foreign priority date has not been perfected. Thus, the priority date of instant application is 9/11/2019 until the foreign priority date is perfected. Restriction 6. Applicant’s election without traverse of Group 1 (claims 1-4 and 9-10) and food or drink composition for type of composition, enteric coated table as the species of formulation, and infertility as the cause/disease associated with the intrauterine bacterial flora in the reply filed on 09/14/2026 is acknowledged. Restriction is deemed to be proper and is made FINAL in this office action. Claims 5-8 are withdrawn from consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claims. There appears to be a discrepancy with the species elected (food or drink and enteric coating). A search was conducted on the elected species, and prior art was found. Claims 3 and 10 are withdrawn from further consideration, as being drawn to nonelected species. The Examiner Claims 1-2, 4 and 9 are examined on the merits in this office action. Please note: claim 10 is withdrawn from further consideration because enteric tablet or enteric capsules appear to be related to pharmaceutical composition. Objections Please note, the specification has not been checked to the extent necessary to determine the presence of all possible error. Applicant's cooperation is required in correcting any errors of which applicant may become aware in the specification. MPEP § 608.01. 7. Claims 2, 4 and 9 are objected to for the following: Claims 2-4 and 9-10 recite, “…to the above-described claim 1…” These should be corrected to recite, “…according to claim 1…” 8. Claim 4 is objected to for the following: Claim 4 does not end with a period. Applicant is required to correct this error. 9. Claims 1-2, 4 and 9 are objected to for the following: Claim numberings are in brackets. The usage of brackets in the claims is confusing because brackets and strikethroughs are used to delete recitation(s) in the claims. Applicant is required to correct this error. Rejections 35 U.S.C. 112(b) 10. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 11. Claim 9 recites the limitation "disturbance in the intrauterine bacterial flora" in the claim, line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 9 is dependent from claim 1. Claim 1 recites, “A method for improving bacterial flora in the uterus…” Claim 1 does not recite, “disturbance in the intrauterine bacterial flora”. Therefore, there is lack of antecedent basis. U.S.C. 102/103 12. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 13. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 14. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 15. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 16. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 17. Claim(s) 1-2, 4 and 9 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by or, in the alternative, under 35 U.S.C. 103 as being unpatentable over Yanaihara et al (Fertility and Sterility, 2007, 87(2): 279-282). 18. Yanaihara et al teach testing the levels of lactoferrin (LF) in follicular fluid (FF) as well as the correlation between the LF concentration of FF, fertilization rate, and embryo quality (see Objective). Yanaihara et al teach that the patients were 35 IVF patients, aged 25-34 years, and follicular fluid was obtained from these patients (see Patients). Yanaihara et al teach the following: PNG media_image1.png 282 390 media_image1.png Greyscale PNG media_image2.png 430 388 media_image2.png Greyscale (p. 281, Discussion). Yanaihara et al teach that oral administration of bovine LF was found to elevate serum IL-18 concentration…shown to be differentially regulated by hormones in the tissue-specific manner…the LF levels of uterine epithelial cells and ovarian steroids positively correlate with circulating estrogen levels…It is thought that LF may be immunologically related to the reproductive process (see p. 281, left column, 2nd paragraph or 1st section reproduced above). Yanaihara et al teach that “LF may be related to fertilization rate and embryo quality…Oocytes with a high LF level in the FF had a significantly higher fertilization rate, and this resulted in higher-quality embryos…” (see p. 281, right column, 1st full paragraph or 2nd section reproduced above). The Examiner has interpreted the bovine LF as “food” composition. Thus, the reference meets the limitations of claims 1-2, 4 and 9. 19. As discussed above, the cited reference disclose an oral administration of bovine LF to 35 IVF patients, aged 25-34 years. The cited reference teaches that LF may be related to fertilization rate and embryo quality. Oocytes with a high LF level in the FF had a significantly higher fertilization rate, and this results in higher-quality embryos. Consequently, the claimed method appears to be anticipated by the reference. 20. In the alternative, even if the claimed method is not identical to the referenced method with regard to some unidentified characteristics, the differences between that which is disclosed and that which is claimed are considered to be so slight that the referenced method is likely to inherently possess the same characteristics of the claimed method particularly in view of the similar characteristics which they have been shown to share. Thus, the claimed method would have been obvious to those of ordinary skill in the art with the meaning of U.S.C. 103. 21. Accordingly, the claimed invention as a whole was at least prima facie obvious, if not anticipated by the reference, especially in the absence of sufficient, clear, and convincing evidence to the contrary. 22. With respect to the art rejection above, please note that Patent and Trademark Office is not equipped to conduct experimentation in order to determine whether Applicants’ product differs and, if so, to what extent, from that of discussed references. Therefore, with the showing of the references, the burden of establishing non-obviousness by objective evidence is shifted to the Applicants. ART OF INTEREST 23. Hashem et al (Biomedical Journal of Scientific & Technical Research, 2021, 29787-29799) teach PNG media_image3.png 434 404 media_image3.png Greyscale (see p. 29795, left column, 1st paragraph of Discussion). 24. Abdel Baky et al (Clin. Exp. Reproduc. Med., 2026, pp. 1-10) teach that lactoferrin treatment ameliorates endometriosis-associated subfertility in a rat model (see Title, Results on p. 1; Discussion on pp. 5-9, and throughout the reference). This is a post filing date reference. CONCLUSION No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JULIE HA whose telephone number is (571)272-5982. The examiner can normally be reached Monday-Thursday 5:00 am- 6:30 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LIANKO GARYU can be reached at 571-270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JULIE HA/Primary Examiner, Art Unit 1654 10/02/2026
Read full office action

Prosecution Timeline

Sep 25, 2024
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773408
ANTI-ISCHEMIC COMPOSITIONS
1y 0m to grant Granted Oct 27, 2026
Patent 12758484
TOPICAL FORMULATIONS OF RECOMBINANT COLLAGENS
5y 0m to grant Granted Oct 13, 2026
Patent 12758481
COSMETIC FORMULATION FOR TOPICAL ADMINISTRATION COMPRISING NOVEL PEPTIDES THAT IMPROVE APPEARANCE AND REGENERATION OF SKIN
4y 2m to grant Granted Oct 13, 2026
Patent 12758618
COMPOSITIONS FOR TREATING RESPIRATORY TRACT INFECTION AND USES THEREOF
4y 0m to grant Granted Oct 13, 2026
Patent 12747280
NEUTROPHIL ELASTASE BINDING PEPTIDES AND COMPOSITIONS THEREOF
4y 2m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+44.0%)
Low
PTA Risk
Based on 1127 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month